NasdaqGM:WVEPharmaceuticals
A Look At Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Development Update
Wave Life Sciences (WVE) has been back on investors’ radar after early data for its RNA obesity candidate WVE-007 showed meaningful fat loss with muscle preservation, along with plans to start a Phase 2a multidose trial in early 2026.
See our latest analysis for Wave Life Sciences.
The recent excitement around WVE-007 and the 2026 pipeline plans helped drive a very strong 90 day share price return of 80.15%, even though the 30 day share price return of 14.26% and year to date share price...